<div data-server-rendered="true" id="__nuxt"><div id="__layout"><div class="outer-container"><div class="content-container"> <div class="answer_container" style="min-height:calc(100vh - 54px);" data-v-0eba195e=""><div class="content_outer_container" data-v-0eba195e=""><div class="share_preview_container" data-v-0eba195e=""><div class="dialog_list" data-v-0eba195e=""><div class="dialog_item" data-v-0eba195e=""><div class="dialog_question fir_dialog_question" data-v-0eba195e=""><div class="question_con" data-v-0eba195e=""><h1 class="fir_question_content" data-v-0eba195e="">
                                    Why did CNSP's EPS remain flat in recent quarters?
                                </h1> <div class="user_slot" data-v-0eba195e=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/default_aime_user.ec532c9.png" alt="user" class="avatar" data-v-0eba195e=""> <span class="user_desction" data-v-0eba195e="">
                                        
                                        4/8/2025 12:22am
                                    </span></div></div></div> <div class="seo-text-answer" data-v-0eba195e="">The EPS of CNS Pharmaceuticals (CNSP) remained flat in recent quarters due to a combination of factors:

1. **Revenue Improvement**: There was an improvement in the company's total operating revenue, from -$5.38 million as of December 31, 2023, to -$3.2 million as of December 31, 2024. This indicates better operational performance, which could contribute to a stable EPS.
2. **Reduced R&amp;D Expenses**: CNS Pharmaceuticals significantly reduced its research and development (R&amp;D) expenses, from $4.27 million in 2023 to $1.49 million in 2024. Since R&amp;D expenses can have a significant impact on net income and, consequently, on EPS, this reduction likely helped maintain EPS stability.
3. **Strategic Adjustments**: The company may have implemented strategic adjustments to optimize market promotion and sales, which could have improved revenue and helped stabilize EPS.

In summary, CNSP's flat EPS in recent quarters can be attributed to a combination of improved revenue, reduced R&amp;D expenses, and strategic adjustments.</div> <div class="dialog_answer" data-v-0eba195e=""><div class="dialog_content" data-v-0eba195e=""><div class="answer_content" data-v-0eba195e=""></div></div></div></div></div> </div></div></div> </div> <div class="extra-module" data-v-261d488f=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/recommend-logo.4f9ccc8.png" alt="right-logo" fetchpriority="high" class="recommend-logo-img" data-v-261d488f=""> <div class="recommend-part" data-v-7790c618="" data-v-261d488f=""><div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/screener-recommend-icon.b007ca8.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime finds your next big stock</span></div> </div> <div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/stock-recommend-icon.77f1c78.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime powers your decisions</span></div> </div></div> </div> <div class="container-mask" style="display:none;"></div></div></div></div><script>window.__NUXT__=(function(a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,A,B,C,D,E,F,G,H,I,J,K,L,M,N,O,P,Q,R,S,T,U,V,W,X,Y,Z,_,$,aa,ab,ac,ad,ae,af,ag,ah,ai,aj,ak,al,am,an){return {layout:"default",data:[{noData:c,currentQuestion:d,textDescription:D,comeFrom:"AInvestShareLink",events:[],answerSource:k}],fetch:{},error:l,state:{sharePreviewModule:{loadJgySuccess:m,dialogRenderList:[{originAnswer:{input_media_info:[],session_round:1,agent_id:a,output_media_info:[],task_id:a,language:a,source:k,cache_builder:a,reply_action:"Answer",execute_mode:w,event_refresh_answer:a,param:"{\"entity_info\":{},\"add_info\":{\"ori_question\":\"Why did CNSP's EPS remain flat in recent quarters?\"},\"event_list\":[],\"client_ip\":\"\",\"question\":\"Why did CNSP's EPS remain flat in recent quarters?\",\"user_id\":\"dp12256364\",\"user_name\":\"\",\"trace_id\":\"226ff083-f8cd-41d4-b116-8231e99d7616\",\"session_id\":\"226ff083-f8cd-41d4-b116-8231e99d7616\",\"source\":\"ths_ainvest_lite_web\",\"input_type\":\"typewrite\"}",agent_info:[{info_type:"search",raw_data:{number:E,title:F,summary:G,full_summary:"Financial Performance CNS Pharmaceuticals (CNSP) reported a total operating revenue of -$3.2 million as of December 31, 2024, compared to -$5.38 million as of December 31, 2023, indicating an improvement in total operating revenue on a year-on-year basis. Although still negative, the loss narrowed, reflecting possible positive changes in the company's operations. Key Financial Data 1. The total operating revenue in 2024 was -$3.2 million, an improvement of approximately 40.5% from -$5.38 million in 2023, indicating an improvement in the company's operating conditions. 2. Research and development expenses in 2024 were $1.49 million, significantly lower than $4.27 million in 2023, showing a reduction in the company's R&D investment. 3. The overall economic environment in the industry gradually recovered from the pandemic, with improved market demand, positively affecting the sales of cns pharmaceuticals. 4. The company may have adjusted its sales strategy, optimizing the effectiveness of market promotion and sales, thus increasing the possibility of revenue. Industry Comparison 1. Industry-wide analysis: The biopharmaceutical industry as a whole experienced recovery from the pandemic, with many companies showing an improvement in revenue in 2024. As one of them, CNS Pharmaceuticals, although still in a loss state, showed a significant improvement compared to other companies in the industry. The industry's total operating revenue in the first three quarters of 2024 decreased by 0.39% year-on-year, and the net profit attributable to parent decreased by 9.01%, but the improvement of cnsp was relatively good. 2. Peer evaluation analysis: Compared with peers, CNS Pharmaceuticals showed a significant improvement in total operating revenue, indicating an increase in its competitiveness in the industry. However, its sustained profitability and future revenue growth potential still need to be monitored, especially in a more competitive environment. Conclusion CNS Pharmaceutica",url:H,image_url:a,video_url:a,publish_time:I,search_extra_info:{search_burial_info:{id:n,uid:n,ab:{scene_id:J,layer_exp:[{layer_id:K,exp_id:L}]}}},msg_id:n}}],answer_chain_name:M,agent_mode:N,native_answer:a,come_from:a,text_answer:D,trace_id:e,cost:14426,event_names:a,question:d,fallback_type:O,input_type:P,fall_back_reason:{fall_back_type:O,risk_detail:{matched_words:[]}},session_id:e,first_return_cost:3741,cache_type:a,question_id:e,transfer_question:d,signal_type:"ON_COMPLETE",start_time:Q,remote_svc:k,slots:[],answer_type:w,user_id:s,skill_name:x},renderList:[{type:"base_info",answer_path:"logs\u002FbaseInfo",logs:[],base_info:{trace_id:e,session_id:e,user_id:s,question:d,source:k,raw_question:d,version:"3.4.1",action_name:x,nlu:{entity:[{type:R,value:"CNSP.O",market:S}]},deep_research:c,deep_thinking:c,agent_mode:N},extra:{}},{answer_path:g,section:{id:h,info_texts:["Thinking"],show_type:i,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"begin"},logs:[],extra:{is_deep_research:c,deep_thinking:c}},{answer_path:g,section:{id:h,info_texts:["Querying Stock: CNSP Revenue, Net Income, Diluted EPS"],show_type:i,choice:[],result_page:{},tag_info_list:[],is_last:b,status:y},logs:[],extra:{action:"Querying Stock",action_input:"CNSP Revenue, Net Income, Diluted EPS",thought:z}},{answer_path:g,section:{id:h,info_texts:["Searching Web: Why does not CNSP Revenue growth"],show_type:i,choice:[],result_page:{},tag_info_list:[],is_last:b,status:y},logs:[],extra:{action:T,action_input:"Why does not CNSP Revenue growth",thought:z}},{answer_path:g,section:{id:h,info_texts:["Searching Web: Why CNSP Net Margin Decrease"],show_type:i,choice:[],result_page:{},tag_info_list:[],is_last:b,status:y},logs:[],extra:{action:T,action_input:"Why CNSP Net Margin Decrease",thought:z}},{answer_path:f,section:{id:U,info_texts:[],show_type:A,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:f,section:{id:U,info_texts:[],show_type:A,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:g,section:{id:h,info_texts:["Generating Answer"],show_type:i,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"ongoing"},logs:[],extra:{}},{answer_path:f,section:{id:t,info_texts:[],show_type:u,voice_txt:"The",text_answer:V,rich_text:V,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:f,section:{id:1001,info_texts:[],show_type:"fenshi",choice:[],result_page:{},tag_info_list:[{stock_info:{code:"CNSP",market_id:S,name:W,domain:R},pos:11,section_id:t,txt:W,jump_type:"pos_fenshi"}],is_last:b},logs:[],extra:{}},{answer_path:f,section:{id:t,info_texts:[],show_type:u,voice_txt:" **",text_answer:X,rich_text:X,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:f,section:{id:2000,info_texts:[],show_type:u,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[{url:H,image_url:a,video_url:a,title:F,summary:G,index:E,publish_time:I,search_id:n,search_uid:n,search_ab:{scene_id:J,layer_exp:[{layer_id:K,exp_id:L}]},jump_type:"normal"}],is_last:b},logs:[],extra:{}},{answer_path:f,section:{id:t,info_texts:[],show_type:u,voice_txt:". This",text_answer:Y,rich_text:Y,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"extraInfo\u002FsourceLink",logs:[],extra:{span_id:a,link_id:a,source:a,link_text:a,link_param:a,link_ids:[]}},{answer_path:g,section:{id:h,info_texts:["Completed"],show_type:i,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"end"},logs:[],extra:{}},{answer_path:"suggest\u002Fquestions",section:{id:10002,info_texts:[],show_type:"result_page",choice:[{display_text:o,query_text:o,trace_info:{item_id:"88c9e031da54f769dc78e3a3759e553a",item_type:j,item_name:o,rec_info:Z}},{display_text:p,query_text:p,trace_info:{item_id:"d6248d77405f66b0c07c813139ca65fc",item_type:j,item_name:p,rec_info:_}},{display_text:q,query_text:q,trace_info:{item_id:"2eddf48f90619d9ed527b7b6c0d95b26",item_type:j,item_name:q,rec_info:$}}],result_page:{components:[{show_type:"lowcode",title_config:{show_type:"title1",data:{h1:a,h2:a},config:{display:c,txt_style:m,type:"1",display2:c,url:a}},request_config:[{source_type:aa,related_name:ab}],puuid:B,tag:a,category:"custom",uuid:ac}],global:{urp_static_data:[{name:ab,value:{status_code:m,columns:[{type:r,index_name:ad,key:ad},{type:r,index_name:ae,key:ae},{type:r,index_name:af,key:af},{type:r,index_name:ag,key:ag},{type:r,index_name:ah,key:ah}],datas:[{send_text:o,item_type:j,rec_info:Z,display_text:o,rec_reason:a},{send_text:p,item_type:j,rec_info:_,display_text:p,rec_reason:a},{send_text:q,item_type:j,rec_info:$,display_text:q,rec_reason:a}],dataSize:aa,status_msg:a}}],lowcode_type:"shunda",interface_request_list:[],lowcode_json:{stack:c,visible:b,childLimit:9999,label:ai,type:"thslc\u002Fthslc-common-container",leaf:c,animate:[],version:"1.0.1",script:[],props:[],path:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fkernel-thslc-resource\u002Fresource\u002Fainvest\u002F0Ae514cfA4\u002Fjs\u002F_thslc-common-container_1.0.1_index.js",isTransparent:b,style:{"background-color":a,"box-shadow":"0px 0px 0px",color:a,width:v,"min-height":"100%",position:aj,height:v},isMaterial:c,id:ai,needTheme:c,hasEditor:c,packed:c,events:[],child:[{readmeUrl:"https:",stack:c,visible:b,customStyle:a,childLimit:m,label:"路径推荐",type:"iwencai\u002FrecommendList",leaf:b,version:"1.12.0",animate:[],url:C,componentUuid:ac,script:[{name:ak,id:20240320,content:"return {\r\n  created: function created() {\r\n    this.isActive = !Boolean(this.$parent.$parent.$parent.$parent.$parent.$parent.question);\r\n    var showId ='tkPanel_bottomTag';\r\n  this.buryPointId = showId;\r\n  }\r\n};"}],props:{recommendList:[],isTransparent:b,renderType:"blue"},path:C,meta:{custom_editor_url:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0editor.js",js_url:C},style:{"background-color":a,margin:"-12px 0px -12px 0px",color:a,display:"block",width:v,position:aj,height:v},isMaterial:b,_id:19,id:ak,hasEditor:b,packed:c,events:[],isSetDefaultValue:b}]}},page:{layout:{layout_data:"[{\"uuid\":\"ztxxx06c0a024223920bbbeb1e0926\",\"showType\":\"lowcode\",\"children\":[]}]"},render_for:al,voice_txt:a,tracking_info:{},uuid:B},order:{is_auto:c,render_for:al,chart_type:"command",puuid:B}},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"suggest\u002Finputs",section:{id:10000,info_texts:[],show_type:"choice",choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"logs\u002Ftrace_debug",section:{id:1005,info_texts:[],show_type:A,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{action_name:x,with_paid_index:c,no_refresh_answer:c,answer_source:{agent_id:a,agent_name:a,execute_mode:w,answer_chain_name:M},is_deep_research:c,deep_thinking:c,create_time:1744086154040},is_last:b}],questionItem:{data:{qStr:d,encodeFlag:c,imageData:l,docsData:[],quoteData:l},tplType:"question"},events:am,agentId:a,param:{entity_info:{},add_info:{ori_question:d},event_list:am,client_ip:a,question:d,user_id:s,user_name:a,trace_id:e,session_id:e,source:k,input_type:P}}],userId:s,userName:a,startTime:Q,mobileType:a,comeFrom:a,textConstants:{},dialogContainer:l,endSignal:c,theme:"white",showTracePopup:c,traceListData:[],chatTraceTargetIndex:m,traceTableData:l,showMask:c}},serverRendered:b,routePath:"\u002Faime\u002Fshare\u002Fcnsps-eps-remain-flat-quarters-e93d8f\u002F",config:{_app:{basePath:an,assetsPath:an,cdnURL:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fiwc-aime-seo\u002F"}}}}("",true,false,"Why did CNSP's EPS remain flat in recent quarters?","226ff083-f8cd-41d4-b116-8231e99d7616","other\u002FopenAnswer","progress\u002Fsearching_for",1000,"searching_for","llm_generated","ths_ainvest_lite_web",null,0,"a41d24fb9ad90294","What are CNSP's key revenue sources and how have they performed recently?","How does CNSP's profit margin compare to industry peers?","What is the current market sentiment towards CNSP's stock?","STR","dp12256364",2001,"rich_text","auto","agent","explain news events","thinking","The user wants to analyze why CNSP's EPS was flat recently. I should focus on the factors that affect EPS, such as revenue, net profit margin, and investment. I will use FinQuery to obtain the aforementioned data, and search for the reasons behind the revenue stagnation and the decline in net profit margin.","signal","39196","\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0index.js","The EPS of CNS Pharmaceuticals (CNSP) remained flat in recent quarters due to a combination of factors:\n\n1. **Revenue Improvement**: There was an improvement in the company's total operating revenue, from -$5.38 million as of December 31, 2023, to -$3.2 million as of December 31, 2024. This indicates better operational performance, which could contribute to a stable EPS.\n2. **Reduced R&D Expenses**: CNS Pharmaceuticals significantly reduced its research and development (R&D) expenses, from $4.27 million in 2023 to $1.49 million in 2024. Since R&D expenses can have a significant impact on net income and, consequently, on EPS, this reduction likely helped maintain EPS stability.\n3. **Strategic Adjustments**: The company may have implemented strategic adjustments to optimize market promotion and sales, which could have improved revenue and helped stabilize EPS.\n\nIn summary, CNSP's flat EPS in recent quarters can be attributed to a combination of improved revenue, reduced R&D expenses, and strategic adjustments.",7,"CNSP Latest Report","2. Uncertainty in the overall economic environment and policy changes may affect the company's long-term growth. 3. Although R&D expenses have ...","https:\u002F\u002Fwww.ainvest.com\u002Fnews\u002Fcnsp-latest-report-2504\u002F","2025-04-01","oeqxkhszf","oeqxkhszf_layer","base","agent_common_v2\nagent-summary","normal_agent","NONE","typewrite",1744086139614,"stock","186","Searching Web",999,"The EPS of CNS Pharmaceuticals (CNSP) remained flat in recent quarters due to a combination of factors:\n\n1.","CNS Pharmaceuticals"," **Revenue Improvement**: There was an improvement in the company's total operating revenue, from -$5.38 million as of December 31, 2023, to -$3.2 million as of December 31, 2024[^7]",". This indicates better operational performance, which could contribute to a stable EPS.\n2. **Reduced R&D Expenses**: CNS Pharmaceuticals significantly reduced its research and development (R&D) expenses, from $4.27 million in 2023 to $1.49 million in 2024[^7]. Since R&D expenses can have a significant impact on net income and, consequently, on EPS, this reduction likely helped maintain EPS stability.\n3. **Strategic Adjustments**: The company may have implemented strategic adjustments to optimize market promotion and sales, which could have improved revenue and helped stabilize EPS[^7].\n\nIn summary, CNSP's flat EPS in recent quarters can be attributed to a combination of improved revenue, reduced R&D expenses, and strategic adjustments.","2+679_496_21_554+0+0+226ff083-f8cd-41d4-b116-8231e99d7616+88c9e031da54f769dc78e3a3759e553a+llm_generated+aimeTagAnalysis+0+0.0785537138581276+1","2+679_496_21_554+0+0+226ff083-f8cd-41d4-b116-8231e99d7616+d6248d77405f66b0c07c813139ca65fc+llm_generated+aimeTagAnalysis+0+0.0668783113360405+2","2+679_496_21_554+0+0+226ff083-f8cd-41d4-b116-8231e99d7616+2eddf48f90619d9ed527b7b6c0d95b26+llm_generated+aimeTagAnalysis+0+0.05288385972380638+3",3,"recommend_query_list","ztxxx06c0a024223920bbbeb1e0926","send_text","item_type","rec_info","display_text","rec_reason","root","relative","iwencai\u002FrecommendList0326","aigc",Array(0),"\u002F"));</script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/b929a16.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/28ccbec.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/d9802b5.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/2077034.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/1e0f8d6.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/7a5f495.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/921844b.js" defer=""></script>